XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Collaborative Arrangements - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Oct. 31, 2023
USD ($)
antibodyDrugConjugate
Feb. 28, 2023
antibodyDrugConjugate
Jul. 31, 2022
USD ($)
May 31, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Amortization             $ 1,582 $ 1,623          
Sales   $ 15,962     $ 14,959   45,485 45,453          
Research and development expense   3,307     4,399   20,904 9,773          
Operating Segments                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Sales   15,663     14,334   44,789 44,146          
Operating Segments | Pharmaceutical                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Sales   14,263     12,963   40,442 39,826          
Lynparza                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Amortization               250          
Lynparza | Other Intangible Assets                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Finite-lived intangible assets   1,600         1,600            
Lenvima                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Amortization   81         154            
Lenvima | Operating Segments | Pharmaceutical                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Sales   260     202   734 660          
Lenvima | Other Intangible Assets                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Finite-lived intangible assets   743         743            
Verquvo | Other Intangible Assets                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Finite-lived intangible assets   51         51            
Adempas | Operating Segments | Pharmaceutical                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Sales   65     57   189 181          
Adempas | Other Intangible Assets                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Finite-lived intangible assets   533         533            
Alliance Revenue - Reblozyl | Operating Segments | Pharmaceutical                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Revenue from collaborative arrangement   52     $ 39   142 124          
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Probable contingent payments     $ 245     $ 600              
Liabilities           $ 600              
Sales-based milestone payments               400          
Eligible future contingent sales-based milestone payments (up to)   2,100         2,100            
Capitalized milestone payment       $ 105         $ 250        
Eligible future contingent regulatory milestone payments (up to)   850         850            
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lenvima                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Probable contingent payments   125   $ 125                  
Liabilities   250         250            
Sales-based milestone payments               600          
Eligible future contingent sales-based milestone payments (up to)   $ 2,300         $ 2,300            
Capitalized milestone payment                 $ 50        
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Sales-based milestone payments               400          
Bristol Myers Squibb Company | Licensing Agreements                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Royalty rate, deduction             0.50            
Bristol Myers Squibb Company | Licensing Agreements | Sales-Based Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent proceeds collaborative arrangement             $ 80            
Bristol Myers Squibb Company | Licensing Agreements | Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Proceeds from collaborators               $ 20          
Bristol Myers Squibb Company | Licensing Agreements | Minimum                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Royalty rate             20.00%            
Bristol Myers Squibb Company | Licensing Agreements | Maximum                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Royalty rate             24.00%            
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Eligible future contingent sales-based milestone payments (up to)                       $ 485 $ 780
Eligible future contingent regulatory milestone payments (up to)                       $ 334  
Number of antibody drug conjugates obtained right and obligations | antibodyDrugConjugate                     7    
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Subsequent Event                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Eligible future contingent sales-based milestone payments (up to)                   $ 3,900      
Eligible future contingent regulatory milestone payments (up to)                   $ 1,950      
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Subsequent Event                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Number of antibody drug conjugates obtained right and obligations | antibodyDrugConjugate                   3      
Aggregate upfront payments due upon execution in collaborative arrangement                   $ 4,000      
Refundable upfront payments in collaborative arrangement                   1,000      
Maximum aggregate contingent milestone payments, per product, in collaborative arrangement                   5,500      
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Subsequent Event | Forecast                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Research and development expense $ 5,500                        
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Ifinatamab Deruxtecan | Subsequent Event                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Refundable upfront payments in collaborative arrangement                   500      
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Patritumab Deruxtecan And Raludotatug Deruxtecan | Forecast                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Aggregate upfront payments due upon lapse of time in collaborative arrangement $ 1,500                        
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Patritumab Deruxtecan | Subsequent Event                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Refundable upfront payments in collaborative arrangement                   500      
Aggregate upfront payments due upon lapse of time in collaborative arrangement                   750      
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Raludotatug Deruxtecan | Subsequent Event                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Aggregate upfront payments due upon lapse of time in collaborative arrangement                   $ 750      
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement, percentage                   75.00%      
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement                   $ 2,000